Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

The Lancet Neurology

Volumn 7, Issue 10, 2008, Pages 903-914

  Mikol, Daniel D ^a   Barkhof, Frederik ^b   Chang, Peter ^c   Coyle, Patricia K ^d   Jeffery, Douglas R ^e   Schwid, Steven R ^f   Stubinski, Bettina ^g   Uitdehaag, Bernard MJ ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c EMD Serono   (United States)

^d STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g Serono International SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; CORTICOTROPIN; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; NATALIZUMAB; STEROID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; CONFIDENCE INTERVALS; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 51449101000     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70200-X     Document Type: Article

References (32)

1. Lassmann H., Bruck W., and Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol 17 (2007) 210-218
2. Lucchinetti C., Bruck W., Parisi J., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47 (2000) 707-717
3. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 (1996) 907-911
4. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
5. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
6. Comi G., Filippi M., Wolinsky J.S., and European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49 (2001) 290-297
7. Panitch H., Goodin D.S., Francis G., et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59 (2002) 1496-1506
8. Durelli L., Verdun E., Barbero P., et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359 (2002) 1453-1460
9. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
10. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
11. Smith S.M., Zhang Y., Jenkinson M., et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17 (2002) 479-489
12. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/reporting/ctc_v30.html (accessed Aug 29, 2008).
13. O'Connor P., Arnason B.G., Comi G., et al. Efficacy, safety and tolerability of 500 μg versus 250 μg interferon beta-1b versus glatiramer acetate in patients with relapsing-remitting multiple sclerosis (the BEYOND study): baseline patient characteristics. European Neurological Society Meeting, Lausanne, Switzerland (May 2006). http://www.akm.ch/ens2006/ (accessed Aug 29, 2008).
14. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
15. Khan O.A., Tselis A.C., Kamholz J.A., et al. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol 8 (2001) 141-148
16. Panitch H., Goodin D., Francis G., et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. For the EVIDENCE study Group and the University of British Columbia MS/MRI Research Group. J Neurol Sci 239 (2005) 67-74
17. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56 (2001) 1496-1504
18. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 53 (1999) 679-686
19. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
20. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 352 (1998) 1491-1497
21. Cohen J.A., Cutter G.R., Fischer J.S., et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59 (2002) 679-687
22. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 (1996) 285-294
23. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
24. Coles A. Efficacy of alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis: analysis after two years of study CAMMS223. Presented at the Annual Meeting of the American Academy of Neurology (2007). http://abstracts2view.com/aan2007boston/ (accessed Aug 29, 2008).
25. Polman C.H., Reingold S.C., Barkhof F., et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 70 (2008) 1134-1140
26. Durelli L., Tavella A., Contessa G., and Clerico M. Evidence-based medicine analysis of immunomodulatory treatment for multiple sclerosis. Eur Neurol Dis 12 (2006) 1-6
27. Francis G.S. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 251 (2004) 42-49
28. Bermel R.A., and Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5 (2006) 158-170
29. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
30. Goeb J.L., Cailleau A., Laine P., et al. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol 26 (2003) 5-7
31. Pandya R., and Patten S. Depression in multiple sclerosis associated with interferon beta-1a (Rebif). Can J Psychiatry 47 (2002) 686
32. Teitelbaum D., Aharoni R., Sela M., and Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA 88 (1991) 9528-9532